TY - JOUR
T1 - Development and targeted use of nilotinib in chronic myeloid leukemia
AU - Fava, Carmen
AU - Kantarjian, Hagop
AU - Cortes, Jorge
AU - Jabbour, Elias
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2008
Y1 - 2008
N2 - The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.
AB - The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.
KW - CML
KW - Imatinib-intolerance
KW - Imatinib-resistance
KW - Nilotinib
UR - http://www.scopus.com/inward/record.url?scp=77953653399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953653399&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:77953653399
SN - 1177-8881
SP - 233
EP - 243
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
IS - 2
ER -